Zhao et al. found that the combination of SU11274 (MET inhibitor) and gefitinib (EGFR inhibitor) could synergistically influence the function of ribosomes to reduce the proliferation of triple-negative breast cancer (TNBC) by reducing the level of ribosomal protein S6 (RPS6).101 In addition, Cordani et al. demonstrated autophagy activation through the formation of autophagic vesicles, in which their fusion with lysosomes by mTOR inhibitor can repress p53- deficient lung, breast, and pancreas cancer-cell growth.102. Here, RPS6 is linked to triple-negative breast carcinoma.